Business
MBX Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Highlights
Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA 12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026 Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 $459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier i
About this update from Mbx Biosciences, Inc.
[{"type":"image","alt":"MBX Biosciences, Inc.","displaySize":"","headline":null,"caption":"MBX Biosciences, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":118,"url":"https://media.zenfs.com/en/globenewswire.com/8cd3831a50ba14ff9e3ffa7d6e7ec405"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/vF54_S_oujQKAjWelEwKDQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2NTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/8cd3831a50ba14ff9e3ffa7d6e7ec405","width":300,"height":118}},"lazy":false},{"type":"text","content":"Phase 3 trial of once-weekly canvuparatide remains on track to initiate in Q3 2026 following recently completed, successful End-of-Phase 2 meeting with FDA","length":155,"tagName":"p"},{"type":"text","content":"12-week MAD Phase 1 data from MBX 4291 for obesity anticipated in Q4 2026","length":73,"tagName":"p"},{"type":"text","content":"Planned nomination of amycretin and GLP-1/GIP/glucagon receptor triple-agonist development candidates for obesity expected in Q2 and Q3 2026 ","length":140,"tagName":"p"},{"type":"text","content":"$459.1 million in pro forma cash and investments as of December 31, 2025, including $85.4 million in net proceeds from top-tier institutional investors through ATM program; expected to support operations into 2029","length":213,"tagName":"p"},{"type":"text","content":"CARMEL, Ind., March 12, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today reported financial results for the fourth quarter and full year ended December 31, 2025, and highlighted recent corporate progress.","length":419,"tagName":"p"},{"type":"text","content":"“2025 was a year of continued growth and execution for MBX, highlighted by the clinical validation of our Precision Endocrine Peptide (PEP™) platform,” said Kent Hawryluk, President and Chief Executive Officer of MBX Biosciences. “Following a successful End-of-Phase 2 meeting with the FDA, we now have a clear path to initiate our Phase 3 trial of once-weekly canvuparatide. We are also advancing a growing obesity pipeline, built on our clinically validated PEPTM platform and designed for once-monthly dosing and improved tolerability. We look forward t...